Martyn is leading the Stratify Genomics team. Prior to Stratify, Gross was advisor then COO of a public company, Dthera Sciences. After setting up the company with a successful clinical trial at UC San Diego, he commercialized a digital therapeutic to provide therapy for dementia and Alzheimer’s Disease. Before that, Gross was CEO and Founder of Skylit Medical, now Clarify Medical. Gross invented a handheld UVB device for psoriasis and eczema patients that connected with physicians and healthcare systems. The company achieved FDA clearance and achieved early sales through an innovative reservation system. Previously, Gross spun out a corporate subsidiary for a marketplace website that achieved 4x profitability and led to a successful acquisition partnership for the parent company.
Gross holds an MBA from Rady School of Management, University of California San Diego, and was named both a Biocom Catalyst Life Science Leader and 2016 Most Influential Innovator by OurCity San Diego Magazine.
A. Karim Kader, MD, PhD
Co-Founder / Board Member / Chief Medical Officer
A. Karim Kader, MD, PhD, is a board-certified urologist who specializes in detecting, treating and preventing prostate cancer.
As a Professor in the Department of Urology and Director of Urologic Oncology at the University of California, San Diego, Dr. Kader instructs medical students, residents and fellows at UC San Diego School of Medicine. His current research interests include genetic markers of risk and outcome in urologic cancer. In addition he is examining the impact of augmented reality and enhanced imaging techniques for education and improved surgical outcomes. Dr. Kader completed a fellowship in urologic oncology at the University of Texas MD Anderson Cancer Center in Houston and a residency in urology at the University of Toronto in Ontario, Canada. He earned his medical degree and doctoral degree from the University of British Columbia in Vancouver, British Columbia. Dr. Kader is board certified in urology.
Dr. Kader is nationally recognized for his expertise in performing robot-assisted radical cystectomy and urinary diversion for patients with bladder cancer. He holds several patents for genetic discoveries focused on the early detection and prevention of prostate cancer in addition to device patents for prostate cancer treatment. He is the principal investigator in numerous clinical research projects and has published extensively.
Co-Founder / Board Member / VP Business Operations
Dalaura Kader is the Co Founder & VP Business Operations of Stratify Genomics. Prior to Stratify Genomics, she directed the launch of the National Regenerative Medicine Foundation establishing strategic initiatives to define regulatory pathways and support collaboration, awareness, research and education in the field of Regenerative Medicine. This generated a commitment for research commercialization which led to the creation of Stratify Genomics.
Ms. Kader started her legal career with the prestigious Canadian law firm Blake Cassels & Graydon prior to moving in house. She gained significant practical & strategic business/M&A experience over the years serving as corporate counsel for several distinguished companies, including Pembina Corporation, Canadian Airlines and Agrifoods International. She most recently served as COO of Pacific Coast Partnership.
Ms. Kader graduated with a BA from the University of Calgary and an LLB from the University of Alberta, Canada.
VP of Research and Development
Dr. Anders Nygren serves as the Vice President of Research and Development at Stratify Genomics. Dr. Nygren focuses on different aspects of nucleic acid analysis, with emphasis on high throughput genotyping using next generation sequencing (NGS). Prior to joining the team, he served as Senior Director, Research and Development at Agena Biosciences located in San Diego, USA. He joined Agena Bioscience, formerly Sequenom in 2008, serving in various roles within the R&D department. Prior to joining Agena/Sequenom, Dr. Nygren helped commercialize the multiplex ligation dependent probe amplification (MLPA) technology for relative quantification of nucleic acid copy numbers, and is the inventor of Methylation-Specific MLPA. Dr. Nygren received his Master of Science in Molecular Biotechnology at Uppsala University and his Ph.D. in clinical chemistry at the Free University of Amsterdam. He has co-authored more than 40 scientific articles and is an inventor on 12 patents/patent applications.
Adam Simpson is the president and chief executive officer of PvP Biologics. He has substantial life science operational and emerging company experience and has executed significant partnering and acquisition transactions. Prior to joining PvP Biologics as president and CEO, he was the president and chief operating officer of Cypher Genomics, a genome interpretation company focused on biomarker discovery to facilitate drug development, through its sale to Human Longevity, Inc. Previously, Mr. Simpson was a co-founder and chief business officer of Meritage Pharma, a company developing treatments for upper gastrointestinal disorders, from company creation through its staged sale to Shire, and at Verus Pharmaceuticals, a company focused on treatments for asthma and anaphylaxis, where as general counsel he led its sale to AstraZeneca and Shionogi. He has been a co-founder of three additional life sciences companies that have either gone public or been acquired. Mr. Simpson started his career as an attorney at Latham & Watkins. He holds a B.S. in biochemistry from the University of California, San Diego, and received his J.D. from the University of Minnesota Law School.
Matt Onaitis was most recently CFO and General Counsel at Cidara Therapeutics. Prior to this, Mr. Onaitis was General Counsel and Secretary of Ignyta. Previously, he was General Counsel and Secretary of Trius Therapeutics, Inc. from May 2013 through its acquisition by Cubist Pharmaceuticals, Inc. in September 2013. Following the acquisition Mr. Onaitis remained with Cubist assisting with the integration through December 2013. Mr. Onaitis was Senior Vice President, General Counsel and Secretary at Somaxon Pharmaceuticals from May 2006 through Somaxon’s acquisition by Pernix Therapeutics Holdings in March 2013. Prior to Somaxon, Mr. Onaitis served as Associate General Counsel at Biogen Idec, as Director, Legal Affairs at Elan Corporation, and in private practice specializing in corporate and commercial law. Mr. Onaitis is a director of SNP Bio, Inc. Mr. Onaitis holds a J.D. from Stanford Law School and a B.S. in mechanical engineering from Carnegie Mellon University.
Robert J. Brown
Robert J. Brown is Chairman and Chief Executive Officer of B&C Associates, Inc., a management consulting, marketing research and public relations firm headquartered in High Point, N.C. He is also the Chairman and CEO of B&C International, Inc., and President of International BookSmart Foundation.
Brown serves as a member of the boards of AutoNation, Inc., North Carolina Railroad Company, High Point University, Virginia Union University, National Urban League, Horatio Alger Association, the Richard Nixon Foundation and the High Point Community Foundation advisory board. He is a retired member of the boards of Duke Energy, Wachovia Corporation and the Sonoco Products Company.